Mammogen Secures Up to $30 Million Series A Financing to Advance RNA-Based Breast Cancer Detection Platform
Mammogen has announced the successful completion of a Series A financing round of up to $30 million, marking a significant milestone in the company's mission to transform breast cancer detection through innovative blood-based diagnostics.
The financing is backed by one of the nation's leading public retirement systems and will provide Mammogen with the resources needed to accelerate development, clinical validation, and commercialization efforts surrounding its proprietary RNA-based breast cancer detection platform.
Mammogen's technology is designed to improve the way breast cancer is detected by leveraging blood-based RNA biomarkers that may help identify disease earlier and more accurately. The company's approach seeks to provide women and healthcare providers with a non-invasive screening solution that has the potential to complement existing breast cancer detection methods and improve patient outcomes.
The new capital will support several key initiatives, including continued advancement of Mammogen's genTRU-breast™ platform, expansion of clinical programs, regulatory activities, strategic partnerships, and growth of the company's operational infrastructure. These efforts are intended to help accelerate the path toward broader adoption and availability of Mammogen's technology.
Breast cancer remains one of the most commonly diagnosed cancers among women worldwide. Despite significant advances in treatment, early detection continues to play a critical role in improving survival rates and long-term outcomes. Mammogen's focus on RNA-based liquid biopsy technology reflects a growing movement within precision medicine to develop less invasive, more accessible diagnostic tools capable of detecting disease earlier in its progression.
The Series A financing underscores growing confidence in Mammogen's scientific approach and long-term vision. As the company advances its clinical and commercial roadmap, this investment positions Mammogen to further its mission of delivering innovative solutions that support earlier detection, more precise diagnosis, and improved care for patients facing breast cancer.
This financing represents an important step forward for Mammogen as it continues working toward a future where blood-based diagnostics can help redefine the standard of care in breast cancer screening and detection.
Read the Full Announcement
For complete details regarding the financing, investors, and forward-looking statements, please read the
original press release published through GlobeNewswire.
